Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Strickler

Showing results (51-60 of 100) with videos related to

Pageof 10
Sort By:
British Journal of Cancer|February 22, 2000
Sexual behaviour, STDs and risks for prostate cancerR B Hayes, L M Pottern, H Strickler, et al.
AME Case Reports|April 29, 2021
A case report of microsatellite instability (MSI)-high, <i>HER2</i> amplified pancreatic adenocarcinoma with central nervous system metastasisNicholas C DeVito, Colm Kelleher, Kyle C Strickland, et al.
The Oncologist|June 14, 2025
A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterationsMargaret C Wheless, Tyler J Zemla, Joleen M Hubbard, et al.
Molecular Cancer Therapeutics|September 5, 2021
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric CancersSamuel J Klempner, Johanna C Bendell, Victoria Meucci Villaflor, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2012
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumorsJohn H Strickler, Alexander N Starodub, Jingquan Jia, et al.
Future Oncology (London, England)|January 6, 2026
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study designNaureen Starling, Elena Elez, John H Strickler, et al.
Annals of Surgical Oncology|August 12, 2020
Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver MetastasesJohn M Creasy, Kyle J Napier, Sarah A Reed, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Tumor <i>NLRP3</i> Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I ExpressionBala Theivanthiran, Nagendra Yarla, Kaylee Villareal, et al.
Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Pageof 10

Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
British Journal of Cancer|February 22, 2000
Sexual behaviour, STDs and risks for prostate cancerR B Hayes, L M Pottern, H Strickler, et al.
AME Case Reports|April 29, 2021
A case report of microsatellite instability (MSI)-high, <i>HER2</i> amplified pancreatic adenocarcinoma with central nervous system metastasisNicholas C DeVito, Colm Kelleher, Kyle C Strickland, et al.
The Oncologist|June 14, 2025
A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterationsMargaret C Wheless, Tyler J Zemla, Joleen M Hubbard, et al.
Molecular Cancer Therapeutics|September 5, 2021
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric CancersSamuel J Klempner, Johanna C Bendell, Victoria Meucci Villaflor, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2012
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumorsJohn H Strickler, Alexander N Starodub, Jingquan Jia, et al.
Future Oncology (London, England)|January 6, 2026
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study designNaureen Starling, Elena Elez, John H Strickler, et al.
Annals of Surgical Oncology|August 12, 2020
Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver MetastasesJohn M Creasy, Kyle J Napier, Sarah A Reed, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Tumor <i>NLRP3</i> Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I ExpressionBala Theivanthiran, Nagendra Yarla, Kaylee Villareal, et al.
Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Pageof 10